Background {#Sec1}
==========

Pulmonary function tests (PFTs) provide objective, quantifiable measures of lung function. They are used to evaluate and monitor diseases that affect heart and lung function, to monitor the effects of environmental, occupational, and drug exposures, to assess risks of surgery, and to assist in evaluations performed before employment or for insurance purposes. Spirometric examination is the most common form of PFT \[[@CR1]\]. According to ATS/ERS guidelines, PFTs may be performed either in the sitting or standing position, and the position should be recorded on the report. Sitting is preferable for safety reasons to avoid falling due to syncope \[[@CR2]\], and might also be more convenient because of the measurement devices and patient comfort. However, people who suffer from neuromuscular disease, morbid obesity, and other conditions may find it difficult to sit or stand during this test, which may influence their results.

One of the main goals of positioning, and specifically the use of upright positions, is to improve lung function in patients with respiratory disorders, heart failure, neuromuscular disease, spinal cord injury (SCI), and obesity, and in the past 20 years, various studies regarding the influence of body position on respiratory mechanics and/or function have been published. However, we did not find a systematic review that integrates findings from studies involving non-mechanically ventilated adults to derive clinical implications for respiratory care and pulmonary function test (PFT) execution.

We aimed to systematically review studies that evaluated the effect of body position on lung function in healthy subjects and non-mechanically ventilated patients with lung disease, heart disease, SCI, neuromuscular disease, and obesity.

Methods {#Sec2}
=======

Two researchers (SK., E-LM.) searched MEDLINE and Google Scholar for studies published from January 1998--December 2017 using the key words body position, lung function, lung mechanics, lung volumes, position change, positioning, posture, PFTs, sitting, standing, supine, ventilation, and ventilatory change, in various combinations. Each search term combination included at least one key word related to pulmonary function and at least one related to body position. The year 1998 was chosen as the beginning point due to the publication of the seminal study by Meysman and Vincken \[[@CR3]\]. A total of 972 abstracts identified in the search were screened by the same two researchers, and full text of 151 potentially relevant articles was obtained. The full texts were evaluated and categorized, and 108 articles not fulfilling the inclusion criteria were excluded (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Study flow diagram

Articles were included if they met the following criteria: (1) Quasi-experimental, pre-post intervention. (2) Two or more body positions compared, including at least the sitting or standing position. (3) Outcome measures included assessment of lung function by forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1), FEV1/FVC, vital capacity (VC), functional residual capacity (FRC), maximal expiratory pressure (PEmax), maximal inspiratory pressure (PImax), peak expiratory flow (PEF), total lung capacity (TLC), residual volume (RV), or diffusing capacity of the lungs for carbon monoxide (DLCO). (4) Study population of non-mechanically ventilated subjects. (5) Participants aged ≥18 years. (6) English language. Studies assessing lung function using other criteria and those without statistical comparisons of lung function in different positions, those enrolling individuals \< 18 years or on mechanical ventilation, published conference abstracts, and systematic reviews were excluded.

Positions studied {#Sec3}
-----------------

Standing -- unsupported active standingSitting -- sitting on a chair or wheelchair with the backrest at 90° and all limbs supportedSupine -- lying flat on the backRight-side lying (RSL) -- lying straight on the right sideLeft-side lying (LSL) -- lying straight on the left side

Outcome measures and defined thresholds for clinical significance {#Sec4}
-----------------------------------------------------------------

FVC -- forced vital capacityChange of 200 ml or 12% from baseline values in FVC \[[@CR4]\]FEV1-- forced expiratory volume in 1 sChange of 200 ml or 12% from baseline values in FEV1 \[[@CR4]\]FEV1/FVC -- forced expiratory volume in 1 s divided by forced vital capacityFEV1/FVC \< 0.7 is defined as obstructive diseaseVC -- vital capacityFRC -- functional residual capacityChange \> 10% \[[@CR5]\]TLC -- total lung capacityChange \> 10% \[[@CR5]\]RV -- residual volumeMaximal expiratory pressure (PEmax)Change ≥24 cmH2O \[[@CR6]--[@CR8]\]Maximal inspiratory pressure (PImax)Change ≤ − 13 cmH2O \[[@CR6]--[@CR8]\]Peak expiratory flow (PEF)Change \> 10% or 60 L/min \[[@CR9], [@CR10]\]Diffusing capacity of the lungs for carbon monoxide (DLCO)Change ≥10% in DLCO \[[@CR11], [@CR12]\]

Two experienced pulmonologists (NA, AR) reviewed the included studies in consensus to identify statistically significant and clinically important differences in pulmonary function. Results from articles included in the review were evaluated by all authors and categorized by study population, body positions studied, and outcome measures. Data from included studies was extracted by four authors (NA, AR, SK, E-LM.) independently and in consultation when questions arose. The review was performed according to the PRISMA guidelines \[[@CR13]\].

Although these are not interventional studies, strictly speaking, we have chosen to assess them as "before and after intervention," wherein the posture/position change is the maneuver of interest. Level of evidence was assessed according to the American Academy of Neurology (AAN) Classification of Evidence for therapeutic intervention \[[@CR14]\]. Risk of bias was assessed according to the Quality Assessment Tool for Before-After (Pre-Post) Studies with No Control Group developed by the National Heart, Lung and Blood Institute (NHLBI) of the US National Institutes of Health (NIH) \[[@CR15]\]. This tool is comprised of 12 questions assessing various aspects of the quality of the study. Two authors (E-LM, SK) independently scored each study using the technique from Kunstler et al. \[[@CR16]\]. Differences were resolved in consensus, in consultation with a third author (YZ). The risk of bias was categorized as low (score 76--100%), moderate (26--75%) or high (0--25%).

Results {#Sec5}
=======

Studies included in the review {#Sec6}
------------------------------

A total of 43 studies fully met inclusion criteria and were included in the review (Fig. [1](#Fig1){ref-type="fig"}). All studies used either consecutive, convenience, or volunteer sampling to enroll healthy individuals or subjects with various medical conditions. All studies provide Class III level of evidence.

The protocols and level of bias in the various studies are shown in Table [1](#Tab1){ref-type="table"} and Additional file [1](#MOESM1){ref-type="media"}: Table S1. Risk of bias was assessed as moderate in 41 studies and low in two. Quality issues were primarily related to sampling techniques for enrolling study participants. All studies used non-random sampling. Some studies investigating healthy subjects included convenience samples of young participants, mainly students. Only 7/43 studies reported sample size calculations required to reach statistical power. In addition, the details of the intervention protocol were not clearly reported in some studies (Table [1](#Tab1){ref-type="table"}) and due to the nature of the study assessors could not be blinded to patient position or outcomes from previous tests.Table 1Study protocols1st Author (year)ProcedurePosture and Test RandomizationAdjustment period to posture prior to measurementRisk of BiasAntunes (2016) \[[@CR45]\]Mini Wright® (Clement Clarke International Ltd. Edinburgh Way Harlow, Essex, UK) peak flow meter portable device with a disposable mouthpieceRandom position order1 minModerateBadr (2002) \[[@CR46]\]Pressure manometer, vitalograph (Compact, Vitalograph Ltd., Buckingham, UK)Random position order\
Random test order (PEF and PEmax) Subjects instructed on equipment use, practiced before test5 minLowBaydur (2001) \[[@CR35]\]SpirometryRandom position orderN/AModerateBen-Dov (2009) \[[@CR17]\]SpirometryN/AN/AModerateBenedik (2009) \[[@CR52]\]Helium dilutionFirst position always sitting5 minModerateCeridon (2011) \[[@CR18]\]Spirometry, DLCO measured by rebreathe techniqueN/A30 min supine position prior to test Time prior to seated measurement not mentionedModerateChang (2005) \[[@CR53]\]Spirometry, FRC measured using helium dilutionFirst position always supine5 minModerateCosta (2015) \[[@CR54]\]Mouth pressure meterRandom position order10 minModerateDe (2012) \[[@CR29]\]SpirometryFirst position was always sittingN/AModerateElkins (2005) \[[@CR47]\]Pressure manometer, spirometry - mass flow sensorRandom position and test order (PEF, PEmax)\
Subjects instructed on equipment use, practiced before test5 minLowFaggiano (1998) \[[@CR58]\]Single breath technique using a Medical Graphics PF/DX module (Medical Graphics St. Paul, Minn, USA) for determining DLCORandom position order10 minModerateGanapathi (2015) \[[@CR19]\]Digital spirometry (BIOPAC System Inc. Goleta, California, USA)N/AN/AModerateGianinis (2013) \[[@CR48]\]Portable peak expiratory flow-deviceRandom position orderN/AModerateKim (2012) \[[@CR36]\]SpirometryN/AN/AModerateLinn (2000) \[[@CR33]\]SpirometryRandom position orderN/AModerateManning (1999) \[[@CR20]\]Spirometry, single breath for determining DLCOTwo protocols (Session A & B). First chosen at random then alternated for successive subjects.\
First position always sitting.15 minModerateMcCoy (2010) \[[@CR49]\]Peak flow meterRandom position order.\
Subjects instructed on equipment use, practiced before testN/AModerateMelam (2014) \[[@CR30]\]Spirometry (Excel/PC-based pulmonary function tests)Random position orderN/AModerateMeysman (1998) \[[@CR3]\]Spirometry, peak flow meterRandom position order10 minModerateMiccinilli (2016) \[[@CR40]\]SpirometryN/AN/AModerateMohammed (2017) \[[@CR31]\]SpirometryOrder of positions always standing, sitting, supine, lateral decubitusN/AModerateMyint (2017) \[[@CR42]\]SpirometryOrder of positions was standing, sitting, supineN/AModerateNaitoh (2014) \[[@CR39]\]Spirometry, breath dynamometer (Chest Co. Ltd)First position always sittingN/AModerateOgiwara (2002) \[[@CR55]\]Vitalpower KH-101 (Chest M.I. Inc., Japan)Random position order10 minModerateOttaviano (2016) \[[@CR50]\]Peak flow meterRandom position orderN/AModeratePalermo (2005) \[[@CR21]\]Spirometry, DLCO measured by a single breath techniqueRandom position order15 minModeratePark (2010) \[[@CR34]\]SpirometryN/AN/AModeratePatel (2015) \[[@CR22]\]SpirometryFirst position always sittingN/AModeratePeces-Barba (2004) \[[@CR56]\]Single breath technique, rebreathing technique for determining DLCON/A3--5 minModeratePoussel (2014) \[[@CR38]\]SpirometryRandom position orderN/AModerateRazi (2007) \[[@CR32]\]SpirometryAlternately sitting, standingN/A 15 min between positionsModerateRoychowdhury (2011) \[[@CR44]\]SpirometryN/AN/A\
5 min rest between positionsModerateSaxena (2006) \[[@CR23]\]SpirometryN/AN/AModerateSebbane (2015) \[[@CR41]\]Spirometry, multiple breath helium dilution methodFirst position always sittingN/AModerateStewart (2000) \[[@CR24]\]Single breath method for determining DLCON/A, 72 h between positions15 minModerateTerson de Paleville (2014) \[[@CR37]\]Spirometry, MP45--36-350 differential pressure transducer Validyne Engineering, (Northridge Ca, USA)First position always sitting30 minModerateTerzano (2009) \[[@CR57]\]Single breath DLCO techniqueRandom position orderAt least 15 minModerateTsubaki (2009) \[[@CR28]\]Micro RPM 01 (Micro Medical, UK), spirometryRandom position orderN/AModerateVarrato (2001) \[[@CR25]\]SpirometryN/AN/AModerateVilke (2000) \[[@CR26]\]SpirometryFirst position always supine/proneN/AModerateWallace (2013) \[[@CR51]\]Peak flow meterRandom position orderN/AModerateWatson (2005) \[[@CR43]\]Multi-breath helium dilution,\
spirometryN/AN/AModerateYap (2000) \[[@CR27]\]Spirometry, FRC was measured using helium dilutionFirst position always sitting5 minModerateRisk of bias was assessed using the Quality Assessment Tool for Before-After (Pre-Post) Studies with No Control Group \[[@CR15], [@CR16]\]*DLCO* Diffusing capacity of the lungs for carbon monoxide, *FRC* Functional residual capacity*N/A* Not available, not reported in the study

A summary of study characteristics, including the positions studied, outcome measures, and main results according to the study population, is shown in Table [2](#Tab2){ref-type="table"}. Out of 43 studies, 29 included healthy subjects, nine included patients with lung disease, four included patients with heart disease, seven included patients with SCI, three included patients with neuromuscular diseases, and four included patients with obesity. Additional file [2](#MOESM2){ref-type="media"}: Table S2 summarizes only the statistically significant findings for each relevant outcome variable, according to position, for each of the populations studied.Table 2Summary of study characteristics according to study population1st Author (Year)No of ParticipantsAge (Years)PopulationPositionsPulmonary FunctionMain FindingsMeysman (1998) \[[@CR3]\]3125.6 ± 3.8HealthySitting Supine\
RSL\
LSLPEF, FVC, FEV1, PImax, PEmaxFVC, FEV1, PEF: sitting\>supine\
LSL, RSL, PImax: sitting\>supine\
PEmax: *p* \> 0.05 between positionsManning (1999) \[[@CR20]\]1962.8 ± 6.8Healthy older adultsSitting\
LSL\
RSLFVC, FEV1 DLCO/VAFVC, FEV1: sitting\>RSL & LSL\
DLCO/VA: *p* \> 0.05 between positionsVilke (2000) \[[@CR26]\]20Range\
18--50Healthy malesSitting\
SupineFVC, FEV1FVC, FEV1: sitting\>supineStewart (2000) \[[@CR24]\]1022.3 ± 2.4Healthy malesSitting SupineFVC, VC, FEV1, FEV1/FVC, PEF, DLCOFVC, PEF: sitting\>supine\
DLCO: sitting\< supine\
FEV1, VC, FEV1/FVC: *p* \> 0.05 between positionsYap (2000) \[[@CR27]\]1062.2±1.2 *Mean±SE*HealthySitting SupineFVC, FEV1, FEV1/FVC, FRCFVC, FEV1, FRC: sitting\>supine\
FEV1/FVC: *p* \> 0.05 between positionsVarrato (2001) \[[@CR25]\]15Mean 41HealthySitting SupineFVCFVC: sitting\>supineBadr (2002) \[[@CR46]\]2534.0 ± 14.9HealthyStanding Sitting Supine\
RSLPEmax, PEFPEmax: standing\>other positions\
PEmax: sitting\>supine & RSL\
PEF: standing\>other positionsOgiwara (2002) \[[@CR55]\]20Mean 22.8±2.1\
Range 21--28HealthySitting\
Supine\
RSL\
LSLPEmax, PImaxPEmax, PImax: *p* \> 0.05 between positionsPeces-Barba (2004) \[[@CR56]\]1437.5±11.5HealthySitting SupineDLCODLCO: sitting\<supineChang (2005) \[[@CR53]\]2028.3 ± 4.8Healthy malesStanding SupineFRCFRC: standing\>supinePalermo (2005) \[[@CR21]\]1461 ± 8HealthySitting Supine\
LSL\
RSLFEV1, FVC, VC, DLCOFEV1, FVC, VC: *p* \> 0.05 between positions\
DLCO: sitting\>LSL & RSLWatson (2005) \[[@CR43]\]5Mean 57HealthySitting SupineTLC, VC, RV, FRCTLC, VC, RV: *p* \> 0.05 between positions\
FRC sitting\>supineSaxena (2006) \[[@CR23]\]80Males 21.3 ± 1.5\
Females 19.6 ± 1.3HealthyStanding Sitting\
SupineFEV1, FVC, FEV1/FVC, PEFFEV1, FVC, PEF: standing\>supine\
FEV1/FVC: sitting\>supineBen-Dov (2009) \[[@CR17]\]744 ± 10HealthySitting SupineFVCFVC: *p* \> 0.05 between positionsTerzano (2009) \[[@CR57]\]1059.0 ± 9.3HealthyStanding Sitting SupineDLCODLCO: *p* \> 0.05 between positionsTsubaki (2009) \[[@CR28]\]1522.7 ± 2.3Healthy femalesSitting SupineFVC, FEV1, FEV1/FVC,\
VC, PImax, PEmaxFEV1/FVC: sitting\>supine\
FVC, FEV1, VC, PImax, PEmax: *p* \> 0.05 between positionsMcCoy (2010) \[[@CR49]\]18223.5 ± 2.5 (healthy and asthmatic patients)HealthyStanding, SittingPEFPEF: *p* \> 0.05 between positionsCeridon (2011) \[[@CR18]\]1263 ± 9HealthySitting SupineFVC, FEV1, FEV1/FVC, DLCOFVC, FEV1, DLCO: sitting\>supine\
FEV1/FVC: *p* \> 0.05 between positionsRoychowdhury (2011) \[[@CR44]\]100Range 19--22HealthySitting SupineVCVC: supine\>sitting in females\
VC: *p* \> 0.05 between positions in malesGianinis (2013) \[[@CR48]\]3022.2 ± 2.4HealthySitting Supine\
RSL\
LSLPEFPEF: sitting\>supine & RSLWallace (2013) \[[@CR51]\]9423.9 ± 3.7HealthyStanding SittingPEFPEF: standing\>sittingNaitoh (2014) \[[@CR39]\]2028 ± 1.4HealthySitting SupineFEV1,VC PEmax, PImaxFEV1, VC: sitting\>supine\
PEmax, PImax: *p* \> 0.05 between positionsCosta (2015) \[[@CR54]\]6319.7 ± 1.5HealthySitting SupinePImax, PEmaxPImax, PEmax: sitting\>supineGanapathi (2015) \[[@CR19]\]20Range 18--25HealthyStanding Sitting Supine\
RSL\
LSLFVC, FEV1, FEV1/FVCFVC, FEV1, FEV1/FVC: standing\>supine, RSL& LSL FEV1: standing\>sitting sitting\>RSL FEV1/FVC: sitting\>LSLPatel (2015) \[[@CR22]\]45Median 21 Range 19--23HealthyStanding, Sitting SupineFVC, FEV1, PEFFVC, FEV1, PEF: sitting\>standing FVC, FEV1, PEF: sitting\>supineAntunes (2016) \[[@CR45]\]3022.7 ± 2.4HealthySitting\
SupinePEFPEF: sitting\>supineMiccinilli (2016) \[[@CR40]\]2033.6 ± 10.5HealthySitting SupineVC, FEV1VC, FEV1: *p* \> 0.05 between positionsOttaviano (2016) \[[@CR50]\]7640 ± 16HealthyStanding SittingPEFPEF: standing\>sittingMyint (2017) \[[@CR42]\]1522.6 ± 2.0HealthyStanding, Sitting\
SupineFEV1/FVCFEV1/FVC: *p* \> 0.05 between positionsBadr (2002) \[[@CR46]\]1166.8 ± 12.6Chronic airflow limitationStanding Sitting Supine\
RSLPEmax, PEFPEmax: standing\>supine & RSL, PEmax: sitting\>supine & RSL\
PEF: standing\>sitting, supine, RSLElkins (2005) \[[@CR47]\]2029 ± 8Adult cystic fibrosisStanding Sitting Supine\
RSLPEmax, PEFPEmax: standing & sitting\>RSL\
PEF: standing\>supine & RSLRazi (2007) \[[@CR32]\]4942.6 ± 11.8Obesity, asthma\
*(Mean BMI 36±5)*Standing SittingFVC, FEV1, FEV1/FVCFVC, FEV1, FEV1/FVC: *p* \> 0.05 between positionsTerzano (2009) \[[@CR57]\]30\
*Mild 10*\
*Moderate-severe 10*\
*Very severe 10*Mild 57.3 ± 8.6\
Moderate-severe 59.8 ± 9.1 Very severe 63.7 ± 5.5COPDStanding Sitting SupineDLCODLCO: *p* \> 0.05 between positionsMcCoy (2010) \[[@CR49]\]2923.5 ± 2.5 (Healthy and asthmatic patients) AsthmaStanding SittingPEFPEF: *p* \> 0.05 between positionsDe (2012) \[[@CR29]\]7561.2 ± 9.2COPDStanding SittingFVC, FEV1FVC, FEV1: *p* \> 0.05 between positionsMelam (2014) \[[@CR30]\]3034.3 ± 3.7AsthmaStanding, Sitting Supine\
RSL\
LSLFVC, FEV1FVC, FEV1: standing\>supineMohammed (2017) \[[@CR31]\]2039.2 ± 8.0AsthmaStanding Sitting Supine\
RSL\
LSLFVC, FEV1, PEFFVC, FEV1, PEF: standing\>supine, RSL, LSL\
FVC, FEV1: standing\>sittingMyint (2017) \[[@CR42]\]1522.3 ± 2.0AsthmaStanding\
Sitting\
SupineFEV1/FVCFEV1/FVC: *p* \> 0.05 between positionsFaggiano (1998) \[[@CR58]\]3259 ± 10CHF, malesSitting SupineDLCODLCO: *p* \> 0.05 between positions\
↓DLCO in sitting in a subgroup of patients with decrease in mean pulmonary arterial pressure in this position\
↑DLCO in sitting in a subgroup of patients with increase in mean pulmonary arterial pressure in this positionYap (2000) \[[@CR27]\]1061.4 ± 2.0 * Mean±SE*CHFSitting SupineFEV1, FVC, FEV1/FVC, VC, FRCFVC, FEV1 VC: sitting\>supine FEV1/FVC, FRC: *p* \> 0.05 between positionsPalermo (2005) \[[@CR21]\]1462 ± 8CHFSitting Supine\
LSL\
RSLFEV1, FVC, VC, DLCOFEV1, FVC: sitting\>RSL & LSL\
DLCO: sitting\>RSL &LSL\
VC: *p* \> 0.05 between positionsCeridon (2011) \[[@CR18]\]2465 ± 8CHFSitting SupineFEV1, FVC, FEV1/FVC, DLCOFEV1, FVC: sitting\>supine FEV1/FVC: *p* \> 0.05 between positions\
DLCO: *p* \> 0.05 between positionsLinn (2000) \[[@CR33]\]222\
*Tetraplegia 98*\
*Paraplegia 124*40 ± 11SCISitting SupineFVC, FEV1, PEFFVC, FEV1, PEF: sitting\<supine in complete tetraplegia\
FVC, FEV1, PEF: *p* \> 0.05 between positions in paraplegiaBaydur (2001) \[[@CR35]\]74\
*C3--7 injury tetraplegia 31 T---L4 injury paraplegia 43*40 ± 12SCISitting SupineFVC, FEV1FVC, FEV1: *p* \> 0.05 between positionsBen Dov (2009) \[[@CR17]\]1242 ± 11Neurologically stable\
*C5--8 tetraplegia*Sitting SupineFVCFVC: sitting\<supinePark (2010) \[[@CR34]\]4335.0 ± 12.6SCI\
*C6-C8*Sitting SupineFVCFVC: sitting\<supineKim (2012) \[[@CR36]\]45\
*Cervical 15*\
*Thoracic 13*\
*Lumbar 17*Cervical 43.2 ± 1.3\
Thoracic 49.8 ± 4.9\
Lumbar 52.2 ± 4.4SCISitting SupineFVC, FEV1FVC, FEV1: *p* \> 0.05 between positions within cervical/thoracic/lumbar subgroups\
FVC, FEV1: sitting\<supine in cervical and thoracic injury\
FVC, FEV1: sitting\>supine in lumbar injury\
Statistically significant difference in the effect of position between cervical/thoracic/lumbar subgroups Terson de Paleville (2014) \[[@CR37]\]27\
*Complete motor injury 13 Incomplete motor injury 14 Cervical 15, Thoracic 12*40 ± 14SCISitting SupineFVC, FEV1, PEmax, PImaxFVC, FEV1: *p* \> 0.05 between positions for all patients together\
FVC: sitting\<supine in cervical/complete motor injury\
FVC: sitting\>supine in thoracic incomplete motor injury\
FEV1 sitting\> supine in incomplete motor injury\
FEV1: sitting\>supine in thoracic incomplete motor injury\
PEmax: sitting\>supine all patients\
PEmax: sitting\>supine in complete motor injury\
PEmax: sitting\>supine in cervical incomplete motor injury\
PImax: *p* \> 0.05 between positions for all patients together\
PImax: sitting\>supine in thoracic complete motor injuryMiccinilli (2016) \[[@CR40]\]20\
*C3--7 tetraplegia 9; T1--8 paraplegia 11*Tetraplegia\
29.4 ± 10.5\
Paraplegia 36.6 ± 10.3SCISitting SupineVC, FEV1VC, FEV1: sitting\<supineVarrato (2001) \[[@CR25]\]3861ALSSitting SupineFVCFVC: sitting\>supinePark (2010) \[[@CR34]\]4554.4 ± 11.1ALSSitting SupineFVCFVC: sitting\>supinePoussel (2014) \[[@CR38]\]5842.6 ± 12.9Myotonic dystrophySitting SupineFVC, FEV1FVC, FEV1: sitting\>supineWatson (2005) \[[@CR43]\]1049 ± 6 *Mean ± SE*Obesity\
Mean BMI 44±3  *Mean±SE*Sitting SupineTLC, VC, RV, FRC,TLC, VC, RV, FRC: *p* \> 0.05 between positionsRazi (2007) \[[@CR32]\]5139.86 ± 10.1Obesity\
*Mean BMI 36.7±4.1*Standing SittingFVC, FEV1, FEV1/FVCFVC, FEV1, FEV1/FVC: *p* \> 0.05 between positionsBenedik (2009) \[[@CR52]\]32Range\
18--75Healthy, mild-moderate obesity\
*Mean BMI 32.7±3.5*Sitting SupineFRCFRC: sitting\>supineSebbane (2015) \[[@CR41]\]1244 ± 14Morbid obesity *Mean BMI 45±5*\
S/P bariatric surgery\
*Mean BMI 31 ± 5*Sitting SupineTLC, RV, VC, FRC, FEV1FEV1: sitting\>supine in morbid obesity\
TLC, RV, FRC, VC: *p* \> 0.05 between positions in morbid obesity\
FRC, FEV1: sitting\>supine in s/p bariatric surgery\
TLC, RV, VC: *p* \> 0.05 between positions in s/p bariatric surgeryValues are mean ± S.D. unless specified other*ALS* Amyotrophic lateral sclerosis, *BMI* Body mass index, *CHF* Congestive heart failure, *COPD* Chronic obstructive pulmonary disease, *DLCO* Diffusing capacity of the lungs for carbon monoxide, *DLCO/VA* Diffusing capacity of the lung for carbon monoxide divided by alveolar volume, *FEV1* Forced expiratory flow in 1 s, *FRC* Functional residual capacity, *FVC* Forced vital capacity, *LSL* Left side lying, *PEF* Peak expiratory flow, *PEmax* Maximal expiratory pressure, *PImax* Maximal inspiratory pressure, *RSL* Right side lying, *RV* Residual volume, *SCI* Spinal cord injury, *S/P* Status post, *TLC* Total lung capacity, *VC* Vital capacity

FVC {#Sec7}
---

The association between FVC and body position in healthy subjects was investigated in 13 studies \[[@CR3], [@CR17]--[@CR28]\]. There was a clinical and statistically significant increase in FVC in sitting vs. supine positions \[[@CR3], [@CR18], [@CR22]--[@CR27]\], in sitting vs. RSL and LSL \[[@CR3], [@CR21]\], standing vs. supine \[[@CR19], [@CR23]\], and standing vs. RSL and LSL \[[@CR19]\]. In a smaller number of studies there was no change between standing and sitting \[[@CR19]\], sitting and supine \[[@CR17], [@CR21], [@CR28]\] or sitting and RSL or LSL \[[@CR21]\], and one study \[[@CR22]\] found a decrease in FVC from sitting to standing that was statistically but not clinically significant. Thus, in the majority of studies the more upright position was associated with increased FVC.

Four studies included subjects with lung disease \[[@CR29]--[@CR32]\]. Among asthmatic patients in one study FVC increased significantly from supine to standing \[[@CR30]\]; however, there was no significant difference between standing and sitting or between sitting and supine, RSL, or LSL. Another study reported a statistically and clinically significant increase in FVC in standing vs. sitting, supine, RSL, and LSL and in sitting vs. supine, RSL and LSL \[[@CR31]\]. Among obese asthmatic patients \[[@CR32]\], and among patients with chronic obstructive pulmonary disease (COPD) \[[@CR29]\], no difference was found in FVC between standing and sitting.

Three studies included subjects with congestive heart failure (CHF) \[[@CR18], [@CR21], [@CR27]\]. In one study, FVC was reported 200 ml higher in sitting vs. RSL and LSL \[[@CR21]\], and in the other two studies FVC was higher in sitting vs. supine by 350--400 ml, which has clinical significance \[[@CR18], [@CR27]\].

Six studies included patients with SCI \[[@CR17], [@CR33]--[@CR37]\]. The effect of body position on FVC depends on the level and extent of injury. Among those with cervical SCI, FVC was higher in the supine vs. sitting position \[[@CR17], [@CR33], [@CR34]\]. Other studies \[[@CR35]--[@CR37]\] did not find significant differences in FVC for patients with SCI in a pooled group of all levels of injury for these positions. However, in patients with cervical SCI, as well as those with thoracic injury in one study \[[@CR36]\], there was an increased FVC in the supine vs. sitting, while in those with thoracic or lumbar injury FVC was higher in the sitting position \[[@CR37]\]. The differences did not always reach statistical significance. Nevertheless, it is important to note that in these debilitated patients with SCI, even a small change in FVC is probably clinically significant.

Three studies evaluated patients with neuromuscular diseases \[[@CR25], [@CR34], [@CR38]\]. In patients with myotonic dystrophy and in those with amyotrophic lateral sclerosis (ALS), there was a clinically and statistically significant decrease in FVC from sitting to supine \[[@CR25], [@CR34], [@CR38]\]. In subjects with obesity (mean BMI 36.7) no significant difference was reported between standing and sitting \[[@CR32]\].

FEV1 {#Sec8}
----

In healthy subjects, FEV1 was reported to be higher in sitting vs. supine \[[@CR3], [@CR18], [@CR22], [@CR23], [@CR26], [@CR27], [@CR39]\], in sitting vs. RSL and LSL \[[@CR3], [@CR19], [@CR20]\], in standing vs. sitting \[[@CR23]\], and in standing vs. sitting, supine, RSL, and LSL \[[@CR19]\]. However, other studies \[[@CR21], [@CR24], [@CR28], [@CR40]\] did not find significant difference for FEV1 between sitting and supine, RSL, and LSL. One study \[[@CR22]\] reported a decrease of 120 ml in FEV1 from sitting to standing, which is statistically but not clinically significant.

Among asthmatic patients, FEV1 was higher in the standing vs. supine position, a statistically and clinically significant change; however, there was no significant difference between sitting vs. supine, RSL, and LSL positions \[[@CR30]\]. Another study in asthmatic patients reported FEV1 to be higher in standing vs. sitting, supine, RSL, and LSL, and in sitting  vs. supine, RSL and LSL \[[@CR31]\]. Among obese asthmatic patients and those with COPD, there was no significant difference in FEV1 between standing and sitting \[[@CR29], [@CR32]\].

In subjects with CHF, one study found a statistically and clinically significant increase in FEV1 in sitting vs. RSL and LSL, but no difference between sitting and supine \[[@CR21]\], while two other studies reported higher FEV1 in sitting vs. supine \[[@CR18], [@CR27]\].

In patients with SCI, FEV1 was recently reported to increase from sitting to supine \[[@CR40]\]; however, other studies found that the effect of position on FEV1 in those with SCI depends on the level and extent of injury. In one study among all subjects with SCI, FEV1 was not significantly influenced by moving from sitting to supine \[[@CR35]\], but patients with cervical injuries showed a tendency for increased FEV1 in the supine vs. sitting position while those with thoracic injuries tended towards increased FEV1 in the sitting position. Along the same vein, another study \[[@CR36]\] found an increase is FEV1 in the sitting vs. the supine position in patients with lumbar injury while FEV1 was higher in the supine position for those with cervical spine or thoracic injuries. Although the differences between positions were not statistically significant, the effect of level of injury was statistically and clinically significant.

In another study \[[@CR33]\], FEV1 was higher in supine vs. sitting in patients with complete tetraplegia, while in patients with incomplete injury there was no significant difference between positions. Another group \[[@CR37]\] reported no significant change in FEV1 between the sitting and supine positions for a pooled group of patients with SCI, but in the subgroup of patients with incomplete motor injury and in those with incomplete thoracic motor injury there was a decrease in the supine position.

In patients with myotonic dystrophy, FEV1 decreased from sitting to supine \[[@CR38]\]. Among those with obesity, FEV1 was higher in sitting vs. supine both before and after bariatric surgery \[[@CR41]\]. In another study among obese patients, there was no difference in FEV1 between standing and sitting \[[@CR32]\].

FEV1/FVC {#Sec9}
--------

Seven studies compared FEV1/FVC for different body positions in healthy subjects \[[@CR18], [@CR19], [@CR23], [@CR24], [@CR27], [@CR28], [@CR42]\]. In several studies, FEV1/FVC was reported to be higher in sitting vs. supine \[[@CR23], [@CR28]\], in sitting vs. LSL \[[@CR19]\], and in standing vs. supine, RSL, and LSL \[[@CR19]\]; however, FEV1/FVC was \> 70% in all body positions so the difference was not clinically significant. Other studies found no difference between sitting and supine \[[@CR18], [@CR24], [@CR27]\] or standing, sitting, and supine \[[@CR42]\].

Among subjects with asthma, CHF, and obesity no statistically significant difference in FEV1/FVC was found between the different body postures \[[@CR18], [@CR27], [@CR32], [@CR42]\].

Vital capacity {#Sec10}
--------------

The effect of body position on vital capacity was evaluated in six studies of healthy subjects \[[@CR21], [@CR24], [@CR28], [@CR39], [@CR43], [@CR44]\]. In most studies no difference was reported between sitting and supine \[[@CR21], [@CR24], [@CR28], [@CR43]\] or between sitting and RSL or LSL \[[@CR21]\]. One study \[[@CR39]\] found that VC was higher in the sitting vs. supine position. However, another study \[[@CR44]\] found that VC was higher in the supine vs. sitting position, but only in females.

In patients with CHF, VC was reported to be higher in sitting vs. supine in one study \[[@CR27]\] while another study found no statistically significant difference between these positions \[[@CR21]\]. In patients with spinal cord injury, VC was higher in the supine vs. sitting position \[[@CR40]\]. In subjects with obesity, no difference in VC was reported between the sitting and supine positions \[[@CR41], [@CR43]\].

PEF {#Sec11}
---

PEF in different body positions was evaluated in 13 studies \[[@CR3], [@CR22]--[@CR24], [@CR31], [@CR33], [@CR45]--[@CR51]\]. Eight studies evaluated only healthy adults \[[@CR3], [@CR22]--[@CR24], [@CR45], [@CR48], [@CR50], [@CR51]\], three evaluated healthy subjects and patients with COPD or asthma \[[@CR31], [@CR46], [@CR49]\], one included adult cystic fibrosis patients \[[@CR47]\], and one included subjects with SCI \[[@CR33]\]. Nine studies that compared standing or sitting positions vs. supine or RSL and LSL found higher PEF in standing and sitting \[[@CR3], [@CR22]--[@CR24], [@CR31], [@CR45]--[@CR48]\]. Three of six studies comparing the standing and sitting positions found higher PEF in standing \[[@CR46], [@CR50], [@CR51]\] and one reported higher PEF in sitting \[[@CR22]\]. However, it is most likely that none of the differences reported in PEF are clinically significant. In SCI patients with complete tetraplegia PEF was found to be 12% higher in the supine vs. sitting position \[[@CR33]\].

FRC {#Sec12}
---

FRC was evaluated using helium dilution in five studies \[[@CR27], [@CR41], [@CR43], [@CR52], [@CR53]\]. Among healthy subjects, FRC was higher in standing \[[@CR53]\] and in sitting \[[@CR27], [@CR43]\] vs. supine, with the differences reaching statistical and clinical significance. However, the difference in sitting vs. supine was not significant among patients with obesity (mean BMI 44--45) \[[@CR41], [@CR43]\] or CHF \[[@CR27]\], and was higher in sitting vs. supine in patients after bariatric surgery (mean BMI 31) \[[@CR41]\]. Another study \[[@CR52]\] involving subjects with mild-to-moderate obesity (mean BMI 32), reported that FRC was significantly higher both statistically and clinically in sitting vs. supine.

Total lung capacity {#Sec13}
-------------------

Two studies that evaluated TLC using helium dilution in healthy subjects \[[@CR43]\] and in subjects with obesity \[[@CR41], [@CR43]\] found no statistically significant difference between the sitting and supine positions.

Residual volume {#Sec14}
---------------

Two studies that evaluated RV using helium dilution in healthy subjects \[[@CR43]\] and those with obesity \[[@CR41], [@CR43]\] found no statistically significant difference between sitting and supine.

PEmax {#Sec15}
-----

Six studies investigated the association between body position and PEmax in healthy subjects \[[@CR3], [@CR28], [@CR39], [@CR46], [@CR54], [@CR55]\]. PEmax was higher in standing vs. supine, in standing vs. sitting and RSL, in sitting vs. supine \[[@CR54]\], and in sitting vs. supine and RSL \[[@CR46]\]; however, the differences reported in those studies were not clinically significant. Other studies found no difference in PEmax between sitting and supine \[[@CR28], [@CR39]\], or between sitting, supine, RSL, and LSL \[[@CR3], [@CR55]\].

In COPD patients, PEmax was higher in standing or sitting vs. supine or RSL \[[@CR46]\], and was higher in standing and sitting vs. RSL in patients with cystic fibrosis \[[@CR47]\]. The differences were not clinically significant.

In subjects with SCI, PEmax was significantly higher in sitting vs. supine for all subjects, and for patients with motor complete injury or incomplete cervical motor injury \[[@CR37]\].

PImax {#Sec16}
-----

In healthy subjects, PImax was improved in sitting vs. supine in two studies \[[@CR3], [@CR54]\]. However, other studies found no difference in PImax in sitting vs. supine \[[@CR28], [@CR39], [@CR55]\], or sitting vs. RSL and LSL \[[@CR3], [@CR55]\]. In subjects with chronic SCI, no significant change was seen in PImax between sitting and supine, with the exception of a subgroup of patients with complete thoracic motor paresis where there was statistically and clinically significant improvement in sitting \[[@CR37]\].

DLCO {#Sec17}
----

Seven studies evaluated the effect of body position on diffusion capacity; six included healthy subjects \[[@CR18], [@CR20], [@CR21], [@CR24], [@CR56], [@CR57]\], three included patients with CHF \[[@CR18], [@CR21], [@CR58]\], and one included COPD patients \[[@CR57]\].

Among healthy subjects, two studies \[[@CR24], [@CR56]\] found statistically and clinically significant improvement in DLCO in supine vs. sitting and one \[[@CR57]\] found a trend towards increased DLCO in supine vs. sitting, however this difference did not reach statistical significance. One study \[[@CR18]\] found DLCO to be higher in the sitting vs. supine positions while another study found no difference in DLCO between these positions \[[@CR21]\]. One study \[[@CR21]\] reported higher DLCO in sitting vs. side lying while another study \[[@CR20]\] found no difference between these positions. In COPD patients, no statistically significant change in DLCO was found between the sitting and the supine position \[[@CR57]\].

Three studies investigated diffusion capacity in patients with CHF \[[@CR18], [@CR21], [@CR58]\]. One study \[[@CR58]\] found that postural changes from the supine to sitting positions induced different responses in diffusion capacity. In some patients diffusion capacity improved in the sitting position and others showed no change or a decline. On the average no statistically significant difference was found between the two positions. The authors attributed the difference in responses to variations in pulmonary circulation pressures. Another study \[[@CR18]\] found no significant difference in diffusion capacity between the sitting and the supine positions. Side-lying was reported to reduce DLCO in comparison to sitting in the third study \[[@CR21]\].

Discussion {#Sec18}
==========

Most studies in this systematic review of 43 papers evaluating the effect of body position on pulmonary function found that pulmonary function improved with more erect posture in both healthy subjects and those with lung disease, heart disease, neuromuscular diseases, and obesity. In patients with SCI, the effect is more complex and depends on the severity and level of injury. In contrast, diffusion capacity, as assessed by DLCO, increases in the supine position in healthy subjects while the effect in CHF patients is thought to depend upon pulmonary circulation pressure.

Decreased FVC in more recumbent positions may reflect both increased thoracic blood volume due to gravitational facilitation of venous return, which is more important in patients with heart failure, as well as cephalic displacement of the diaphragm due to abdominal pressure in the recumbent positions, which is more important in obese subjects \[[@CR59]\]. In side-lying positions, even though only the dependent hemi-diaphragm is displaced, the effect on FVC appears to be similar to that observed in a supine position \[[@CR59]\]. Other factors that may contribute to lower FVC values in side-lying positions include increased airway resistance and decreased lung compliance secondary to anatomical differences between the left and right lungs, as well as shifting of the mediastinal structures \[[@CR20]\].

FEV1 was also higher in erect positions. Recumbent positions limit expiratory volumes and flow, which may reflect an increase in airway resistance, a decrease in elastic recoil of the lung, or decreased mechanical advantage of forced expiration, presumably affecting the large airways \[[@CR20]\]. In asthmatic patients the increase in FVC while standing might be due to the increased diameter of the airways in this position \[[@CR30]\].

In patients with CHF the lungs are stiff and heavy, and the heart is large and heavy, increasing the negative effects of lung-heart interdependence \[[@CR60]\]. As cardiac dimension increases, lung volume, mechanical function, and diffusion capacity decrease \[[@CR61], [@CR62]\]; thus, the heart weighs on the diaphragm while sitting and on one of the lungs while in a side-lying position. This influences the ability of the lungs to expand laterally but allows the diaphragm to descend and the lungs to expand inferiorly. In side-lying positions, the heart weighs on one lung, compressing both the airways and lung parenchyma, leading to a reduction in FEV1 and FVC due to airway compression \[[@CR21]\]. Both elastic (reduced lung compliance) and resistive loads are simultaneously increased in the supine position in CHF patients \[[@CR63]\].

Changes in FVC from the sitting to supine positions may reflect diaphragm strength/paralysis. FVC is thus an important clinical tool for assessment of diaphragmatic weakness in patients with neuromuscular diseases \[[@CR64]\]. In patients with ALS, supine FVC is a test of diaphragmatic weakness \[[@CR65]\] that predicts orthopnea \[[@CR25]\] and prognosis for survival \[[@CR66], [@CR67]\]. The American Academy of Neurology has concluded that in ALS patients, supine FVC is probably more effective than erect FVC in detecting diaphragm weakness and correlates better with symptoms of hypoventilation \[[@CR68]\].

In patients with cervical SCI (tetraplegia), FVC and FEV1 increase in the supine vs. sitting position. The diaphragm increases its inspiratory excursion in the supine position because its muscle fibers are longer at end expiration, and they operate at a more effective point of their length-tension curve \[[@CR69]--[@CR71]\]. This mechanism is especially important in patients for whom the diaphragm is the main muscle for breathing, since their intercostal and abdominal muscles are inactive due to SCI.

FRC was reported to increase in upright positions in healthy subjects \[[@CR27], [@CR43], [@CR53]\] and in patients with mild-to-moderate obesity \[[@CR41], [@CR52]\]. Changing from a supine to an upright position increases FRC due to reduced pulmonary blood volume and the descent of the diaphragm. This may change the point in which tidal breathing occurs in the volume-pressure curve, which leads to increased lung compliance, and thus an identical pressure change would produce a greater inspired volume if there is no change in respiratory drive \[[@CR53]\]. However, among patients with CHF, no difference in FRC between sitting and supine was reported \[[@CR27]\]. In heart failure, reduction in lung compliance in the supine position might reduce the passive change in lung volume, but FRC may be sustained above relaxation volume by an adjustment in respiratory muscle or glottal activity \[[@CR27]\]. Among patients with obesity the sitting FRC was less than in healthy subjects but there was no further decrease in the supine position \[[@CR43]\].

PEF, PEmax, and PImax were found to increase in upright positions in healthy subjects \[[@CR3], [@CR23], [@CR24], [@CR46], [@CR48], [@CR50], [@CR51]\] and in those with lung diseases \[[@CR31], [@CR46], [@CR47]\]. This may be related to changes in lung volumes with positions.

Standing and sitting have been shown to lead to the highest lung volumes \[[@CR72], [@CR73]\]. At higher lung volumes the elastic recoil of the lungs and the chest wall is greater. In addition, the expiratory muscles are at a more optimal region of the length-tension curve and thus are capable of generating higher intrathoracic pressure, potentially generating higher expiratory pressures and pushing air through narrow airways at high speed, which results in higher PEmax, PEF, and FEV1. As lung volumes decrease, muscle length becomes less optimal, which results in lower PEmax in sitting, compared to the standing position, and even lower in more recumbent positions. The change in PEmax influences PEF \[[@CR46]\].

When standing, gravity pulls the mediastinal and abdominal structures down, creating more space in the thoracic cavity, which allows further expansion of the lungs and greater lung volumes \[[@CR74]\]. This, along with the decrease in compression on the lung bases, allows alveoli to recruit and increases lung compliance. The inspiratory muscles can expand even more, which allows the diaphragm to continue contracting downwards, thus increasing lung volumes \[[@CR46]\].

Sitting often leads to the somewhat reduced lung volumes compared with standing. This can be explained by several mechanisms. First, in sitting, abdominal organs are higher, interfering with diaphragmatic motion, thus enabling smaller inspiration. Second, the abdominal muscles are in a less optimal point in the length-tension curve, since the combination of hip flexion and higher position of the abdominal contents exert upward pressure. Third, the back of the chair may limit thoracic expansion. These three factors explain a slightly lower PEmax and PEF in sitting vs. standing \[[@CR46]\].

Diaphragmatic strength is negatively affected by the supine position, and intrathoracic blood volume is increased. These factors lead to decreased PEmax and PEF in the supine position \[[@CR3]\].

In side-lying positions (RSL or LSL), when the bed is flat, the abdominal contents fall forward. The dependent hemi-diaphragm is stretched to a good length for tension generation, while the nondependent hemi-diaphragm is more flattened. Changes in lung volumes may thus balance themselves out due to a better diaphragmatic contraction but decreased space in the thorax \[[@CR46]\].

The decreased PImax observed in the supine position could be related to diaphragm overload by abdominal content displacement during maximal inspiratory effort, which could offset improved diaphragm position on the length-tension curve. In addition, the length of all other inspiratory muscles may become less optimal in supine position \[[@CR75]\].

In patients with cervical spinal cord injury and high tetraplegia, PEF was found to be higher in the supine vs. sitting position \[[@CR33]\] corresponding to the increase in FVC and FEV1 in the supine position.

In healthy subjects, most studies showed an increase in DLCO in supine vs. sitting \[[@CR24], [@CR56], [@CR57]\]. This improvement is attributed to the moderate increase in alveolar blood volume in the supine position due to recruitment of lung capillary bed on transition from upright to supine. Age may attenuate this increase \[[@CR76]\]. This may explain why a study that included participants with a mean age of 61 \[[@CR21]\] found no difference in DLCO between sitting and supine.

In side-lying positions, the heart weighs on one lung, compressing both airways and lung parenchyma, reducing alveolar blood volume, and causing ventilation/ perfusion mismatch. Those effects caused reduction of diffusion capacity in the side-lying positions \[[@CR21]\].

In COPD patients, there was no change in DLCO between sitting and supine \[[@CR57]\]. This might be related to reduced FVC and alveolar damage in these patients. These effects might have negative impact on diffusion capacity, opposing the positive effect of the increase in blood volume in the alveoli \[[@CR57]\].

In patients with CHF, different patterns of the effect of posture on DLCO were observed \[[@CR58]\]. The change in DLCO was probably related to the change in alveolar blood volume, most likely due to differences in pulmonary artery pressure and heart dimensions \[[@CR58]\].

Limitations of the study {#Sec19}
------------------------

There are a few limitations to this review. First, the level of evidence of the studies is relatively low. However, in this type of research, due to the nature of the populations studied and the interventions applied, it is impossible to perform a randomized control study. Second, most studies were performed on a small number of subjects and all studies used either consecutive, convenience, or volunteer sampling. The review included only adult subjects and it is therefore not possible to generalize the results to children and adolescents. Finally, research protocols varied between studies and detailed information about protocols were often missing. Patient cooperation during lung function testing strongly influences results. This may explain contradictory results obtained in some cases. Studies that included subjects older than 60 years did not mention the cognitive function of participants, a factor that may influence patient cooperation.

Further research in this field is needed, including studies designed to evaluate lung function in a larger number of healthy participants as well as in individuals with a variety of medical conditions. There is also a need to use a standardized protocol including randomization of postures and times between tests (e.g. for wash-out of inhaled gasses or redistribution of blood volume) in different positions to enable a better comparison of outcomes.

Conclusions {#Sec20}
===========

When performing pulmonary function tests, body position plays a role in its influence over test results. As seen in this review, a change in body position may have varying implications depending on the patient populations. American Thoracic Society (ATS) guidelines \[[@CR2]\] recommend performing PFTs in the sitting or standing position, but the sitting position is usually preferred. The norms of those functions according to gender and age were established from tests performed in this position. This review suggests that for most of the subjects this is the preferred position for the test; however, clinicians should consider performing PFTs in other positions in selected patients. In patients with SCI, testing also in the supine position may provide important information. In patients with neuromuscular disorders, performing PFTs in the supine position may help to assess diaphragmatic function.

Positioning plays an important role in maximizing respiratory function when treating patients with various problems and diseases and it is important to know the implications of each position on the respiratory system of a specific patient. Understanding the influence of body position can give healthcare professionals better knowledge of optimal positions for patients with different diseases.
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AAN

:   American Academy of Neurology

ALS

:   Amyotrophic lateral sclerosis

ATS

:   American Thoracic Society

CHF

:   Congestive heart failure

COPD

:   Chronic obstructive pulmonary disease

DLCO

:   Diffusing capacity of the lungs for carbon monoxide

ERS

:   European Respiratory Society

FEV1

:   Forced expiratory volume in 1 s

FRC

:   Functional residual capacity

FVC

:   Forced vital capacity

LSL

:   Left side lying

PEF

:   Peak expiratory flow

PEmax

:   Maximal expiratory pressure

PFT

:   Pulmonary function test

PImax

:   Maximal inspiratory pressure

RSL

:   Right side lying

RV

:   Residual volume

SCI

:   Spinal cord injury

TLC

:   Total lung capacity

VC

:   Vital capacity
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